Dr Tom Ford

Dr Tom Ford

Conjoint Senior Lecturer

School of Medicine and Public Health

Career Summary

Biography

Tom is a patient-centred Interventional Cardiologist living on the Central Coast of NSW. He was born in Edinburgh, Scotland and attended the University of Dundee graduating from medicine aged 22 receiving the University Medal (Captain WA Low Prize 2007).

He emigrated to Australia 10 years ago after gaining the MRCP at the Royal College of Physicians in Edinburgh. In 2015, he completed his FRACP during advanced cardiology training in Sydney (Prince of Wales Hospital and St George Hospital). In 2019, Dr Ford returned from a three-year fellowship in Glasgow (Golden Jubilee National Hospital). This centre has the largest volume for coronary stents in the UK and his cardiology training in two continents exposed him to a high volume of interventional cardiology procedures including complex cardiac intervention, acute emergency percutaneous coronary intervention (i.e. emergency intervention for heart attack), advanced multimodal coronary imaging, structural heart interventions and invasive therapies for resistant hypertension. During his time in Glasgow, he performed research into coronary artery disease performing an internationally recognized clinical trial involving state-of-the-art invasive testing for angina patients helping to improve their quality of life. His PhD was submitted in 2019 to the University of Glasgow and won the Bellahouston Medal as the highest distinction for the excellence of theses submitted for the degrees of MD, DDS and PhD. This work is directly relevant to help diagnose and manage patients with angina, chest pain and/or breathlessness.

He is a Senior Clinical Lecturer at University of Newcastle, an Honorary Clinical Lecturer at the University of Glasgow and an Honorary Conjoint Associate at University of New South Wales, Sydney. Dr Ford is the Australian National Young Ambassador to EAPCI (European Association for Percutaneous Coronary Intervention), the NSW cardiology representative for the RACP  advanced training committee and is a Fellow of the Cardiac Society for Australia/New Zealand (FCSANZ). He has spoken as invited faculty at all major cardiology scientific sessions including the American Heart Association (AHA), European Society of Cardiology (ESC), EuroPCR, and Transcatheter Cardiovascular Therapeutics (TCT in USA). His research has been published in leading cardiology journals and was recently recognized with two accolades firstly from the European wide PCR organization (EuroPCR Best Abstract – Winner PCR’s got talent) and secondly from the British Cardiac Society (‘Best of the Best’ Clinical Abstract – Interventional Cardiology).

Outside of work Tom loves living on the beach and is a keen golfer, surfer, runner and enjoys spending time with his wife Naomi and their dog, Maisie.


Keywords

  • Cardiovascular medicine
  • Complex Percutaneous Coronary Interventions
  • Coronary physiology
  • Interventional Cardiology

Fields of Research

Code Description Percentage
110201 Cardiology (incl. Cardiovascular Diseases) 100
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Journal article (44 outputs)

Year Citation Altmetrics Link
2020 Morrow AJ, Ford TJ, Mangion K, Kotecha T, Rakhit R, Galasko G, et al., 'Rationale and design of the Medical Research Council's Precision Medicine with Zibotentan in Microvascular Angina (PRIZE) trial: Precision medicine for microvascular angina', American Heart Journal, 229 70-80 (2020)

© 2020 Elsevier B.V. Microvascular angina is caused by cardiac small vessel disease, and dysregulation of the endothelin system is implicated. The minor G allele of the non-coding... [more]

© 2020 Elsevier B.V. Microvascular angina is caused by cardiac small vessel disease, and dysregulation of the endothelin system is implicated. The minor G allele of the non-coding single nucleotide polymorphism (SNP) rs9349379 enhances expression of the endothelin 1 gene in human vascular cells, increasing circulating concentrations of ET-1. The prevalence of this allele is higher in patients with ischemic heart disease. Zibotentan is a potent, selective inhibitor of the ETA receptor. We have identified zibotentan as a potential disease-modifying therapy for patients with microvascular angina. Methods: We will assess the efficacy and safety of adjunctive treatment with oral zibotentan (10 mg daily) in patients with microvascular angina and assess whether rs9349379 (minor G allele; population prevalence ~36%) acts as a theragnostic biomarker of the response to treatment with zibotentan. The PRIZE trial is a prospective, randomized, double-blind, placebo-controlled, sequential cross-over trial. The study population will be enriched to ensure a G-allele frequency of 50% for the rs9349379 SNP. The participants will receive a single-blind placebo run-in followed by treatment with either 10 mg of zibotentan daily for 12 weeks then placebo for 12 weeks, or vice versa, in random order. The primary outcome is treadmill exercise duration using the Bruce protocol. The primary analysis will assess the within-subject difference in exercise duration following treatment with zibotentan versus placebo. Conclusion: PRIZE invokes precision medicine in microvascular angina. Should our hypotheses be confirmed, this developmental trial will inform the rationale and design for undertaking a larger multicenter trial.

DOI 10.1016/j.ahj.2020.07.007
2020 Suda A, Takahashi J, Beltrame JF, Berry C, Camici PG, Crea F, et al., 'International prospective cohort study of microvascular angina Rationale and design', IJC Heart and Vasculature, 31 (2020)

© 2020 The Authors Background: Patients with signs and symptoms of myocardial ischemia and non-obstructive coronary artery disease (CAD) frequently have coronary functional abnorm... [more]

© 2020 The Authors Background: Patients with signs and symptoms of myocardial ischemia and non-obstructive coronary artery disease (CAD) frequently have coronary functional abnormalities, including coronary microvascular dysfunction. Those with the latter are grouped under the term ¿microvascular angina¿ (MVA). Although diagnostic criteria exist for MVA, as recently proposed by our COVADIS (COronary VAsomotor Disorders International Study) group and the condition has been increasingly recognized in clinical practice, the clinical characteristics and long-term prognosis of MVA patients in the current era remain to be fully elucidated. Aims: In the present study, we aimed to prospectively assess the clinical characteristics and long-term prognosis of MVA subjects in the current era in an international, multicenter, observational, and prospective registry study. Methods: A total of 15 medical centers across 7 countries (USA, UK, Germany, Spain, Italy, Australia, and Japan) enrolled subjects fulfilling the COVADIS diagnostic criteria for MVA as follows; (1) signs and/or symptoms of myocardial ischemia, (2) absence of obstructive CAD, and (3) objective evidence of myocardial ischemia and/or coronary microvascular dysfunction. The primary endpoint was the composite of major cardiovascular events (MACE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospitalization due to heart failure or unstable angina. Between July 2015 and December 2018, a total of 706 subjects with MVA (M/F 256/450, 61.1 ± 11.8 [SD] yrs.) were registered. Subjects will be followed for at least 1 year. The present study will provide important information regarding the clinical characteristics, management, and long-term prognosis of MVA patients in the current era.

DOI 10.1016/j.ijcha.2020.100630
2020 Sidik NP, McEntegart M, Roditi G, Ford TJ, McDermott M, Morrow A, et al., 'Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Function and CT Coronary Angiogram (CorCTCA) study', AMERICAN HEART JOURNAL, 221 48-59 (2020)
DOI 10.1016/j.ahj.2019.11.015
Citations Scopus - 5Web of Science - 6
2020 McCartney PJ, Maznyczka AM, Eteiba H, McEntegart M, Oldroyd KG, Greenwood JP, et al., 'Low-Dose Alteplase During Primary Percutaneous Coronary Intervention According to Ischemic Time', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 75 1406-1421 (2020)
DOI 10.1016/j.jacc.2020.01.041
Citations Scopus - 2Web of Science - 2
2020 Hennigan B, Berry C, Collison D, Corcoran D, Eteiba H, Good R, et al., 'Percutaneous coronary intervention versus medical therapy in patients with angina and grey-zone fractional flow reserve values: a randomised clinical trial', HEART, 106 758-764 (2020)
DOI 10.1136/heartjnl-2019-316075
Citations Scopus - 3Web of Science - 1
2020 Ford TJ, Stanley B, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al., '1-Year Outcomes of Angina Management Guided by Invasive Coronary Function Testing (CorMicA)', JACC-CARDIOVASCULAR INTERVENTIONS, 13 33-45 (2020)
DOI 10.1016/j.jcin.2019.11.001
Citations Scopus - 10Web of Science - 10
2020 Ford TJ, Ong P, Sechtem U, Beltrame J, Camici PG, Crea F, et al., 'Assessment of Vascular Dysfunction in Patients Without Obstructive Coronary Artery Disease: Why, How, and When', JACC: Cardiovascular Interventions, 13 1847-1864 (2020) [C1]

© 2020 The Authors Ischemic heart disease secondary to coronary vascular dysfunction causes angina and impairs quality of life and prognosis. About one-half of patients with sympt... [more]

© 2020 The Authors Ischemic heart disease secondary to coronary vascular dysfunction causes angina and impairs quality of life and prognosis. About one-half of patients with symptoms and signs of ischemia turn out not to have obstructive coronary artery disease, and coronary vascular dysfunction may be relevant. Adjunctive tests of coronary vasomotion include guidewire-based techniques with adenosine and reactivity testing, typically by intracoronary infusion of acetylcholine. The CorMicA (Coronary Microvascular Angina) trial provided evidence that routine management guided by an interventional diagnostic procedure and stratified therapy improves angina and quality of life in patients with angina but no obstructive coronary artery disease. In this paper, the COVADIS study group provide a comprehensive review of why, how, and when coronary vascular dysfunction should be assessed invasively. They discuss the rationale through a shared understanding of vascular pathophysiology and clinical evidence. They propose a consensus approach to how an interventional diagnostic procedure is performed with focus on practical aspects. Finally, the authors discuss the clinical scenarios in patients with stable and acute coronary syndromes in which measurement of coronary vascular function may be helpful for patient care.

DOI 10.1016/j.jcin.2020.05.052
Citations Scopus - 1
2020 Maznyczka AM, McCartney PJ, Eteiba H, Greenwood JP, Muir DF, Chowdhary S, et al., 'One-Year Outcomes After Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention The T-TIME Randomized Trial', CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 13 (2020)
DOI 10.1161/CIRCINTERVENTIONS.119.008855
2020 Fong LCW, Ford TJ, Costa BR, Juni P, Berry C, 'Bias and Loss to Follow-Up in Cardiovascular Randomized Trials: A Systematic Review', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 9 (2020) [C1]
DOI 10.1161/JAHA.119.015361
2020 Ford TJ, Corcoran D, Padmanabhan S, Aman A, Rocchiccioli P, Good R, et al., 'Genetic dysregulation of endothelin-1 is implicated in coronary microvascular dysfunction.', Eur Heart J, 41 3239-3252 (2020)
DOI 10.1093/eurheartj/ehz915
2020 Ford TJ, Berry C, 'Angina: contemporary diagnosis and management', Heart (British Cardiac Society), 106 387-398 (2020) [C1]
DOI 10.1136/heartjnl-2018-314661
Citations Scopus - 1Web of Science - 1
2019 McCartney PJ, Eteiba H, Maznyczka AM, McEntegart M, Greenwood JP, Muir DF, et al., 'Effect of Low-Dose Intracoronary Alteplase During Primary Percutaneous Coronary Intervention on Microvascular Obstruction in Patients With Acute Myocardial Infarction A Randomized Clinical Trial', JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 321 56-68 (2019)
DOI 10.1001/jama.2018.19802
Citations Scopus - 26Web of Science - 24
2019 Ubaid S, Ford TJ, Berry C, Murray HM, Wrigley B, Khan N, et al., 'Cangrelor versus Ticagrelor in Patients Treated with Primary Percutaneous Coronary Intervention: Impact on Platelet Activity, Myocardial Microvascular Function and Infarct Size: A Randomized Controlled Trial', THROMBOSIS AND HAEMOSTASIS, 119 1171-1181 (2019)
DOI 10.1055/s-0039-1688789
Citations Scopus - 7Web of Science - 6
2019 Maznyczka AM, Ford TJ, Oldroyd KG, 'Revascularisation and mechanical circulatory support in patients with ischaemic cardiogenic shock', HEART, 105 1364-1374 (2019)
DOI 10.1136/heartjnl-2018-313050
Citations Scopus - 2Web of Science - 2
2019 Ford TJ, Corcoran D, Sidik N, Oldroyd KG, Rocchiccioli P, McEntegart M, Berry C, 'MINOCA: Requirement for Definitive Diagnostic Work-Up', HEART LUNG AND CIRCULATION, 28 E4-E6 (2019)
DOI 10.1016/j.hlc.2018.04.001
Citations Scopus - 1
2019 Morrow A, Ford TJ, Brogan R, 'Incidence of acute bronchospasm during systemic adenosine administration for coronary angiography clinical', Journal of the Royal College of Physicians of Edinburgh, 49 204-206 (2019)

© 2019, Royal College of Physicians of Edinburgh. All rights reserved. Background Adenosine is frequently used during coronary angiography to induce hyperaemia and allow operators... [more]

© 2019, Royal College of Physicians of Edinburgh. All rights reserved. Background Adenosine is frequently used during coronary angiography to induce hyperaemia and allow operators to perform quantitative measurements of lesion severity. Acute bronchospasm is a recognised side effect relating to the activation of ¿off target¿ A2B receptors. The true incidence of severe bronchospasm relating to adenosine administration is not known. Methods Using an electronic patient database, we analysed 100,253 consecutive coronary angiograms over almost 19 years. Fractional flow reserve (FFR) was measured under systemic adenosine in 9,440 cases. Results Adenosine-related bronchospasm was reported in only five cases (0.05%). One case resulted in a life-threatening respiratory arrest. Conclusions This study reveals the incidence of acute bronchospasm during FFR testing to be extremely low. Although rare, these reactions can be severe and are not simply limited to patients with brittle airways disease. Physicians should be aware of the utility of bolus intravenous aminophylline providing targeted therapy to reverse and treat adenosine-related bronchospasm.

DOI 10.4997/JRCPE.2019.307
Citations Scopus - 2
2019 Ford TJ, Khan A, Docherty KF, Jackson A, Morrow A, Sidik N, et al., 'Sex differences in procedural and clinical outcomes following rotational atherectomy', CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 95 232-241 (2019)
DOI 10.1002/ccd.28373
Citations Scopus - 3Web of Science - 3
2019 Ford TJ, Berry C, 'How to diagnose and manage angina without obstructive coronary artery disease: Lessons from the British heart foundation CorMicA trial', Interventional Cardiology Review, 14 76-82 (2019)

© 2020 American Society for Microbiology. All rights reserved. Patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (INOCA) present a diagno... [more]

© 2020 American Society for Microbiology. All rights reserved. Patients with symptoms and/or signs of ischaemia but no obstructive coronary artery disease (INOCA) present a diagnostic and therapeutic challenge. Microvascular and/or vasospastic angina are the two most common causes of INOCA; however, invasive coronary angiography lacks the sensitivity to diagnose these functional coronary disorders. In this article, the authors summarise the rationale for invasive testing in the absence of obstructive coronary disease, namely that correct treatment for angina patients starts with the correct diagnosis. They provide insights from the CORonary MICrovascular Angina (CorMicA) study, where an interventional diagnostic procedure was performed with linked medical therapy to improve patient health. Identification of these distinct disorders (microvascular angina, vasospastic angina or non-cardiac chest pain) is key for stratifying INOCA patients, allowing prognostic insights and better patient care with linked therapy based on contemporary guidelines. Finally, they propose a framework to diagnose and manage patients in this common clinical scenario.

DOI 10.15420/icr.2019.04.R1
Citations Scopus - 3
2019 Ford TJ, Yii E, Sidik N, Good R, Rocchiccioli P, McEntegart M, et al., 'Ischemia and No Obstructive Coronary Artery Disease Prevalence and Correlates of Coronary Vasomotion Disorders', CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 12 (2019)
DOI 10.1161/CIRCINTERVENTIONS.119.008126
Citations Scopus - 4Web of Science - 4
2019 Berry C, Sidik N, Pereira AC, Ford TJ, Touyz RM, Kaski J-C, Hainsworth AH, 'Small-Vessel Disease in the Heart and Brain: Current Knowledge, Unmet Therapeutic Need, and Future Directions', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 8 (2019)
DOI 10.1161/JAHA.118.011104
Citations Scopus - 14Web of Science - 13
2019 Adamson C, Rocchiccioli P, Brogan R, Berry C, Ford TJ, 'Post-operative myocardial infarction following aortic root surgery with coronary reimplantation: A case series treated with percutaneous coronary intervention', European Heart Journal - Case Reports, 3 (2019)

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. Background Coronary ostial stenosis is an uncommon but potentially leth... [more]

© The Author(s) 2019. Published by Oxford University Press on behalf of the European Society of Cardiology. Background Coronary ostial stenosis is an uncommon but potentially lethal complication following aortic root replacement with or without aortic valve replacement (including Bentall and David procedures). This manifests clinically as acute myocardial ischaemia in the early or late post-operative period. Traditionally, this might be managed with redo open-heart surgery. Case summary This case series describes two presentations where urgent percutaneous coronary intervention was used to manage myocardial infarction complicating aortic root surgery with coronary reimplantation. Discussion This series highlights the risk of acute myocardial infarction after cardiac surgery involving coronary reimplantation. Emergency percutaneous coronary intervention is feasible and illustrates the importance of shared post-operative care involving the cardiac surgeons and the cardiology team.

DOI 10.1093/ehjcr/ytz181
Citations Scopus - 1
2019 Cacciottolo TM, Perikari A, van der Klaauw A, Henning E, Stadler LKJ, Keogh J, et al., 'Scientific Business Abstracts of the 113th Annual Meeting of the Association of Physicians of Great Britain and Ireland', QJM : monthly journal of the Association of Physicians, 112 724-729 (2019)
DOI 10.1093/qjmed/hcz175
2018 Ford TJ, Corcoran D, Oldroyd KG, McEntegart M, Rocchiccioli P, Watkins S, et al., 'Rationale and design of the British Heart Foundation (BHF) Coronary Microvascular Angina (CorMicA) stratified medicine clinical trial', AMERICAN HEART JOURNAL, 201 86-94 (2018)
DOI 10.1016/j.ahj.2018.03.010
Citations Scopus - 9Web of Science - 9
2018 Weisbord SD, Gallagher M, Jneid H, Garcia S, Cass A, Thwin S-S, et al., 'Outcomes after Angiography with Sodium Bicarbonate and Acetylcysteine', NEW ENGLAND JOURNAL OF MEDICINE, 378 603-614 (2018)
DOI 10.1056/NEJMoa1710933
Citations Scopus - 160Web of Science - 140
2018 Ford TJ, 'Coronary physiology and prognosis - What does pressure-bounded coronary flow reserve add?', INTERNATIONAL JOURNAL OF CARDIOLOGY, 261 32-34 (2018)
DOI 10.1016/j.ijcard.2018.03.032
2018 Ford TJ, Rocchiccioli P, Good R, McEntegart M, Eteiba H, Watkins S, et al., 'Systemic microvascular dysfunction in microvascular and vasospastic angina', EUROPEAN HEART JOURNAL, 39 4086-4097 (2018)
DOI 10.1093/eurheartj/ehy529
Citations Scopus - 39Web of Science - 36
2018 Ford TJ, Corcoran D, Sidik N, McEntegart M, Berry C, 'Coronary Microvascular Dysfunction Assessment of Both Structure and Function', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 72 584-586 (2018)
DOI 10.1016/j.jacc.2018.03.545
Citations Scopus - 2Web of Science - 3
2018 Ford TJ, Stanley B, Good R, Rocchiccioli P, McEntegart M, Watkins S, et al., 'Stratified Medical Therapy Using Invasive Coronary Function Testing in Angina The CorMicA Trial', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 72 2841-2855 (2018)
DOI 10.1016/j.jacc.2018.09.006
Citations Scopus - 69Web of Science - 63
2018 Ford TJ, Corcoran D, Berry C, 'Stable coronary syndromes: pathophysiology, diagnostic advances and therapeutic need', HEART, 104 284-292 (2018)
DOI 10.1136/heartjnl-2017-311446
Citations Scopus - 38Web of Science - 37
2018 Ford TJ, Nguyen K, Brassil J, Kushwaha V, Friedman D, Allan R, et al., 'Balloon Aortic Valvuloplasty in the Transcatheter Valve Era: Single Centre Indications and Early Safety Data in a High Risk Population', HEART LUNG AND CIRCULATION, 27 595-600 (2018)
DOI 10.1016/j.hlc.2017.05.128
Citations Scopus - 4Web of Science - 4
2018 Ford TJ, McEntegart M, Berry C, Oldroyd KG, 'Arterial Access for Invasive Coronary Angiography: The 'Left Backhander'', HEART LUNG AND CIRCULATION, 27 E98-E99 (2018)
DOI 10.1016/j.hlc.2018.02.021
Citations Scopus - 2Web of Science - 2
2018 Ford TJ, Rocchiccioli P, 'SPOT DIAGNOSIS A keen eye for risk', BMJ-BRITISH MEDICAL JOURNAL, 360 (2018)
DOI 10.1136/bmj.j5884
2018 Ford TJ, McCartney P, Corcoran D, Collison D, Hennigan B, McEntegart M, et al., 'Single- Versus 2-Stent Strategies for Coronary Bifurcation Lesions: A Systematic Review and Meta-Analysis of Randomized Trials With Long-Term Follow-up', JOURNAL OF THE AMERICAN HEART ASSOCIATION, 7 (2018)
DOI 10.1161/JAHA.118.008730
Citations Scopus - 16Web of Science - 16
2018 Corcoran D, Ford TJ, Hsu LY, Chiribiri A, Orchard V, Mangion K, et al., 'Rationale and design of the coronary microvascular angina cardiac magnetic resonance imaging (CorCMR) diagnostic study: The CorMicA CMR sub-study', Open Heart, 5 (2018)

© © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY. Published by BMJ. Introduction Angina with no obstructive coronary artery disease (ANOCA) is a common synd... [more]

© © Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY. Published by BMJ. Introduction Angina with no obstructive coronary artery disease (ANOCA) is a common syndrome with unmet clinical needs. Microvascular and vasospastic angina are relevant but may not be diagnosed without measuring coronary vascular function. The relationship between cardiovascular magnetic resonance (CMR)-derived myocardial blood flow (MBF) and reference invasive coronary function tests is uncertain. We hypothesise that multiparametric CMR assessment will be clinically useful in the ANOCA diagnostic pathway. Methods/analysis The Stratified Medical Therapy Using Invasive Coronary Function Testing In Angina (CorMicA) trial is a prospective, blinded, randomised, sham-controlled study comparing two management approaches in patients with ANOCA. We aim to recruit consecutive patients with stable angina undergoing elective invasive coronary angiography. Eligible patients with ANOCA (n=150) will be randomised to invasive coronary artery function-guided diagnosis and treatment (intervention group) or not (control group). Based on these test results, patients will be stratified into disease endotypes: microvascular angina, vasospastic angina, mixed microvascular/vasospastic angina, obstructive epicardial coronary artery disease and non-cardiac chest pain. After randomisation in CorMicA, subjects will be invited to participate in the Coronary Microvascular Angina Cardiac Magnetic Resonance Imaging (CorCMR) substudy. Patients will undergo multiparametric CMR and have assessments of MBF (using a novel pixel-wise fully quantitative method), left ventricular function and mass, and tissue characterisation (T1 mapping and late gadolinium enhancement imaging). Abnormalities of myocardial perfusion and associations between MBF and invasive coronary artery function tests will be assessed. The CorCMR substudy represents the largest cohort of ANOCA patients with paired multiparametric CMR and comprehensive invasive coronary vascular function tests. Ethics/dissemination The CorMicA trial and CorCMR substudy have UK REC approval (ref.16/WS/0192). Trial registration number NCT03193294.

DOI 10.1136/openhrt-2018-000924
Citations Scopus - 3
2017 Ford TJ, Corcoran D, Berry C, 'Coronary artery disease: physiology and prognosis', EUROPEAN HEART JOURNAL, 38 1990-1992 (2017)
DOI 10.1093/eurheartj/ehx226
Citations Scopus - 5Web of Science - 3
2017 Roy JR, Sun P, Ison G, Prasan AM, Ford T, Hopkins A, et al., 'Selective anti-scatter grid removal during coronary angiography and PCI: a simple and safe technique for radiation reduction', INTERNATIONAL JOURNAL OF CARDIOVASCULAR IMAGING, 33 771-778 (2017)
DOI 10.1007/s10554-017-1067-5
Citations Scopus - 6Web of Science - 7
2017 Ford TJ, Berry C, De Bruyne B, Yong ASC, Barlis P, Fearon WF, Ng MKC, 'Physiological Predictors of Acute Coronary Syndromes Emerging Insights From the Plaque to the Vulnerable Patient', JACC-CARDIOVASCULAR INTERVENTIONS, 10 2539-2547 (2017)
DOI 10.1016/j.jcin.2017.08.059
Citations Scopus - 19Web of Science - 15
2016 Ford T, Rees D, 'Patent ductus arteriosus illuminating an old eponym', BMJ-BRITISH MEDICAL JOURNAL, 353 (2016)
DOI 10.1136/bmj.i2182
2015 Robaei D, Ford T, Ooi S-Y, 'Ankyrin-B Syndrome: A Case of Sinus Node Dysfunction, Atrial Fibrillation and Prolonged QT in a Young Adult', Heart Lung and Circulation, 24 E31-E34 (2015)
DOI 10.1016/j.hlc.2014.09.013
Citations Scopus - 7Web of Science - 6
2014 Ford TJ, Fong MW, Cheah BC, Alexopolous C, 'Pulmonary hypertension and hepatic encephalopathy: lethal complications of Rendu-Osler-Weber disease.', J R Coll Physicians Edinb, 44 126-129 (2014)
DOI 10.4997/JRCPE.2014.207
2013 Ford TJ, Cranney G, Li A, 'An ECG that changed in a febrile patient', BMJ-BRITISH MEDICAL JOURNAL, 346 (2013)
DOI 10.1136/bmj.f585
Citations Web of Science - 1
2010 Ford T, Whitworth C, Dhaun N, 'Minerva', BMJ, 340 c2887 (2010)
DOI 10.1136/bmj.c2887
Citations Scopus - 1
2008 Ford TJ, Dillon JF, 'Minocycline hepatitis', EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 20 796-799 (2008)
DOI 10.1097/MEG.0b013e3282f493c5
Citations Scopus - 21Web of Science - 16
2007 Camilleri M, Vazquez-Roque MI, Burton D, Ford T, Mckinzie S, Zinsmeister AR, 'Pharmacodynamic effects of a novel prokinetic 5-HT4 receptor agonist, ATI-7505, in humans', NEUROGASTROENTEROLOGY AND MOTILITY, 19 30-38 (2007)
DOI 10.1111/j.1365-2982.2006.00865.x
Citations Web of Science - 79
Show 41 more journal articles

Conference (1 outputs)

Year Citation Altmetrics Link
2020 Monjur MR, Said CF, Bamford P, Parkinson M, Szirt R, Ford TJ, 'BIODEGRADABLE POLYMER SIROLIMUS ELUTING STENT (ORSIRO) VERSUS SECOND GENERATION DURABLE POLYMER DRUG ELUTING STENTS: A META-ANALYSIS OF RANDOMISED TRIALS', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Chicago, IL (2020)
Edit

Research Supervision

Number of supervisions

Completed0
Current1

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2019 Honours Ultrathin-strut biodegradable polymer versus durable polymer drug-eluting stents
Mentorship and supervision of undergraduate medical research project. We performed a prospective systematic review and meta-analysis of ultra thin strut drug eluting stent (with bioresorbable polymer) versus contemporary durable polymer drug eluting stent designs (PROSPERO CRD147136).
General Medicine, NEWCASTLE UNIVERSITY Principal Supervisor
Edit

Dr Tom Ford

Position

Conjoint Senior Lecturer
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email tom.ford@newcastle.edu.au
Link Twitter

Office

Location Gosford Hospital
Cnr Henry Parry Drive and Margin Street
Gosford, NSW 2250
Australia
Edit